Immunoreactivity of MIC2 (CD99) in Acute Myelogenous Leukemia and Related Diseases
Authors:
- Paul J ZhangPZPaul J Zhang
- Maurice BarcosMBMaurice Barcos
- John J BrooksJBJohn J Brooks
- 1 April 2000
- journal article
- Published by Elsevier in Laboratory Investigation
- Vol. 13 (4) , 452-458
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- MIC2, TdT, bcl-2, and CD34 expression in paraffin-embedded high-grade lymphoma/acute lymphoblastic leukemia distinguishes between distinct clinicopathologic entitiesHuman Pathology, 1997
- Immunohistochemical Profile of Monoclonal Antibody 013American Journal of Surgical Pathology, 1994
- Immunocytochemical study of 12E7 in small round‐cell tumours of childhood: an assessment of its sensitivity and specificityHistopathology, 1993
- Comparison of Cell Surface Antigen HBA71 (p30/32MIC2), Neuron-Specific Enolase, and Vimentin in the Immunohistochemical Analysis of Ewingʼs Sarcoma of BoneAmerican Journal of Surgical Pathology, 1992
- Terminal transferase positive acute myeloid leukemia: Immunophenotypic characterization and response to induction therapyHematological Oncology, 1989
- Terminal deoxynucleotidyl transferase positive acute myeloid leukaemia: an association with immature myeloblastic leukaemiaBritish Journal of Haematology, 1988
- TdT activity in acute myeloid leukemias defined by monoclonal antibodiesAmerican Journal of Hematology, 1986
- Incidence of TdT Positivity in Cases of Leukemia and LymphomaActa Haematologica, 1986
- Granulocytic sarcoma of the clavicleJournal of Pediatric Hematology/Oncology, 1982
- A human thymus-leukemia antigen defined by hybridoma monoclonal antibodies.Proceedings of the National Academy of Sciences, 1979